{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T23:13:23Z","timestamp":1772925203867,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T00:00:00Z","timestamp":1554768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Protalix"},{"DOI":"10.13039\/100008484","name":"Biomarin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Amicus Therapeutics"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.ymgme.2019.03.010","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T22:18:29Z","timestamp":1554329909000},"page":"86-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial"],"prefix":"10.1016","volume":"127","author":[{"given":"Uma","family":"Ramaswami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel G.","family":"Bichet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorne A.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4809-1274","authenticated-orcid":false,"given":"Gabriela","family":"Dostalova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Fainboim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Fellgiebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassiano M.","family":"Forcelini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"An Haack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Hopkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Mauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behzad","family":"Najafian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Ronald","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suma P.","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth L.","family":"Thurberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"T\u00f8ndel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Tylki-Szymanska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9331-0926","authenticated-orcid":false,"given":"Bernard","family":"B\u00e9nichou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frits A.","family":"Wijburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2019.03.010_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0010","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","article-title":"Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry","volume":"64","author":"Hopkin","year":"2008","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/gim.2014.120","article-title":"Fabry disease in infancy and early childhood: a systematic literature review","volume":"17","author":"Laney","year":"2015","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0020","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1651-2227.2006.tb02186.x","article-title":"Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey","volume":"95","author":"Ramaswami","year":"2006","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0025","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease","volume":"79","author":"Najafian","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0030","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria","volume":"51","author":"T\u00f8ndel","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0035","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical Fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0040","author":"U.S. Food & Drug Administration"},{"key":"10.1016\/j.ymgme.2019.03.010_bb0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"4","author":"T\u00f8ndel","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0050","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymgme.2015.10.007","article-title":"The management and treatment of children with Fabry disease: a United States-based perspective","volume":"117","author":"Hopkin","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0055","doi-asserted-by":"crossref","first-page":"e0124987","DOI":"10.1371\/journal.pone.0124987","article-title":"Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial","volume":"10","author":"Wijburg","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2019.03.010_bb0060","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.0022-202X.2004.22425.x","article-title":"Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies","volume":"122","author":"Thurberg","year":"2004","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0065","doi-asserted-by":"crossref","first-page":"e0152812","DOI":"10.1371\/journal.pone.0152812","article-title":"One year of enzyme replacement therapy reduces globotriaosylceramide inclusions in podocytes in male adult patients with Fabry disease","volume":"11","author":"Najafian","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2019.03.010_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.389","article-title":"Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female Fabry patients: a multicenter Fabry Registry study","author":"Germain","year":"2018","journal-title":"Mol. Genet. Genomic Med."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0075","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","article-title":"Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease","volume":"152","author":"Wraith","year":"2008","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0085","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0090","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/GIM.0b013e3181981d82","article-title":"Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease","volume":"11","author":"Lubanda","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0095","doi-asserted-by":"crossref","first-page":"e47805","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2019.03.010_bb0100","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12967-017-1146-3","article-title":"Assessment of plasma chitotriosidase activity, CCL18\/PARC concentration and NP-C suspicion index in the diagnosis of Niemann-pick disease type C: a prospective observational study","volume":"15","author":"De Castro-Or\u00f3s","year":"2017","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0105","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bcmd.2005.05.005","article-title":"Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease","volume":"35","author":"Deegan","year":"2005","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0110","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/ndt\/gfp658","article-title":"Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate","volume":"25","author":"T\u00f8ndel","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0115","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.amjcard.2017.04.016","article-title":"Arrhythmia and clinical cardiac findings in children with Anderson-Fabry disease","volume":"120","author":"Wilson","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0120","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpeds.2005.03.004","article-title":"Radiological evidence of early cerebral microvascular disease in young children with Fabry disease","volume":"147","author":"Cabrera-Salazar","year":"2005","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0125","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1399-0004.2012.01947.x","article-title":"Fabry disease in children: agalsidase-beta enzyme replacement therapy","volume":"83","author":"Borgwardt","year":"2013","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0130","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ad.2012.03.014","article-title":"Fabry disease and the clinical spectrum of angiokeratomas","volume":"104","author":"Guinovart","year":"2013","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0135","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s10545-017-0051-5","article-title":"Hearing loss in children with Fabry disease","volume":"40","author":"Suntjens","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0140","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1136\/bjo.2009.176651","article-title":"Fabry disease in children: correlation between ocular manifestations, genotype and systemic clinical severity","volume":"94","author":"Allen","year":"2010","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0145","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000369309","article-title":"Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria","volume":"129","author":"T\u00f8ndel","year":"2015","journal-title":"Nephron"},{"key":"10.1016\/j.ymgme.2019.03.010_bb0150","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0155","first-page":"807","article-title":"Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients","volume":"32","author":"Skrunes","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0160","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease","volume":"96","author":"B\u00e9nichou","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0165","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1681\/ASN.2014121226","article-title":"Serum-mediated inhibition of enzyme replacement therapy in Fabry disease","volume":"27","author":"Lenders","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0170","article-title":"Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease","author":"Lenders","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2019.03.010_bb0175","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGENETICS.116.001691","article-title":"\u03b1-Galactosidase A genotype N215S induces a specific cardiac variant of Fabry disease","volume":"10","author":"Oder","year":"2017","journal-title":"Circ. Cardiovasc. Genet."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218307662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218307662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:24:13Z","timestamp":1761089053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719218307662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1096719218307662"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.03.010","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}